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Introduction 
The incidence of Hereditary Ovarian Cancer Syndromes (HOCS) in the United States and Western
Europe is less than 1% of all epithelial ovarian cancers1,2. There are three types of clinical syndromes
that come under this heading; breast-ovarian cancer syndrome, site-specific ovarian cancer syndrome
and familial cancer syndrome (Lynch syndrome II). Mode of inheritance of these syndromes is
autosomal dominant and the risk of developing ovarian cancer in individuals belonging to these
families is as high as 50%3. Genetic linkage studies have demonstrated that the gene which predisposes
to breast and ovarian cancer (BRCA I) is located on chromosome 17q. BRCAI carriers’ life time risk of
getting breast or ovarian cancer approaches 100%4,5. Clinically, these familial cancers are characterized
by early age at onset and higher frequency of bilateral involvement. Pathologically, these tumors often
tend to be poorly differentiated. This article presents three Pakistani families identified to be affected
by HOCS. Importance of detailed family history and pedigree analysis in the identification of these




The proband (III/40) belonging to family number 1 (Figure 1) is a 46 year female with poorly
differentiated ovarian cancer stage fib diagnosed in 1993. She undenvent staging laparotorny and
cytoreductive surgery for a pelvic mass. Post-operatively she received six courses ofcisplatinum and
cyclophosphamide. She has been regularly followed up and has been in remission till the last follow-
up.
Her family history (Figure 1) revealed two of her elder sisters diagnosed as having breast cancer(III/38,
III/39) at 31 and 47 years of age respectively. One of them had already expired. Her detailed family
history was taken and pedigree was made including paternal lineage and 2nd and 3rd degree relatives.
It reveals that fotlr of her paternal aunts had suffered from some kind of reproductive cancers. Of these,
two had ovarian cancer diagnosed at ages of 45 and 49 years respectively (II/I II/3), one had breast
cancer diagnosed at the age of 40 years (11/4) and one had endometrial cancer (II/2), Among the
siblings of (LI/i and 1114), two have already been diagnosed with breast cancerat the age of3 I and 34
years respectively (III/5,III/18). One of them expired a year after the diagnosis. A paternal uncle (II/6)
has four affected siblings, three diagnosed as breast cancer (III/28, III/29, III/30) at 42, 41 and 44 years
of age respectively and one as ovarian cancer (III/31) at 47 years. Three of them had already expired.
There are several family members at continuing risk of cancer.
Family 2
The proband is a60 yearold female who presented with abdominal pain in May 1992.Ultrasound
revealed gallstones and she was scheduled for laparoscopic cholecystectomy. At laparoscopy, nodular
masses were observed involving the omentum, small bowel and pelvis. The procedure was abandoned
after taking biopsies from these masses. Histopathological examination of biopsy specimen revealed
metastatic adenocarcinoma. She underwent hysterectomy, bilateral salpingoophrectorny, ileal resection,
partial omentectorn)’ and cholecystectomy in June, 1992. Histopathology confirmed papillary
adenocarcinoma of left ovary involving omentum and small bowel stage (IIIC). Post-operatively she
received six cycles of carboplatinum and Ifosfamide combination chemotherapy. In February, 1993, she
underwent second look laparotorny which was negative and four cycles of intraperitoneal etoposide
and carboplatinum were given. She is having regular follow-ups including CA-125 levels which are
within normal limits.
Her family history revealed, 10 family members who arc affected by some gynecological malignancy
(Figure 2).
Among her sisters, one has already expired after being diagnosed as a case ofepithelial ovarian cancerat
the age of 50 years (111/23). The other sister was receiving chemotherapy for the same problem and
later on expired in 1994 (III/24). Her mother also died of the same disease at the age of 52 years (1115).
One of her nieces (IV/44) also died of ovarian cancer at the age of 35 years. One of her paternal aunts
had breast cancer (II/I)and two paternal cousins have breast (111/14) and ovarian (III/15) cancer
respectively. Now in the third generation of the families of her paternal cousins there has already been
two cases of breast cancer (IV/9, IV/32) and one has already expired.
Family 3
The proband belonging to this family was 44 years old female who was discovered to have a pelvic
mass during a routine gynaecologic examination. She was counseled to undergo this examination
because of the strong family history of ovarian cancer (Figure 3).
Her elder sister and one of the maternal aunts had been under treatment for this problem.
Herclinical examination and later MRI revealed a 10cm size pelvic mass. Her Ca 125 levels were
raised. She underwent staging laparotomy and cytoreductive surgery in April 1993. Histopathology
revealed bilateral poorly differentiated endometroid carcinoma of ovary with metastatic seedlings on
sigmoid colon and bladder peritoneum (stage IIIC). Post-operatively, she received six cycles of
chemotherapy. She was in remission when she died suddenly after a myocardial infarction in 1995.
Her sisteralso died at the age of42 afterbeing diagnosed a year earlier (IV/14) to have ovariancancer.
Hermaternal aunt (111/6) expired in 1994. Her detailed family history revealed that her mother (11114)
had also died of the same disease and one of the maternal aunts of her mother (II/2) had some sort of
intra abdominal malignancy.
Discussion 
Hereditary ovarian cancer syndrome(HOCS) requires to be differentiated from ordinary familial
ovarian cancers; a terminology used to describe any ovarian cancer patient who has a close relative
with the same disease. The former is a small subset of this category in which there is familial clustering
of ovarian as well as other cancers such as breast, endometrial or colorectal cancers in a pattern of
inheritance consistent with autosomal dominant mode of transnussion. Autosomal dominant mode can
be suspected if mother, paternal aunt or approximately half of the sisters are affected by the disease.
The exact genetic risk of acquiring clinical disease is difficult to assess because of variable penetrance
and expression of the inherited trait, however, it could be as high as 40-50%. In the absence of reliable
biomarkers of acceptable sensitivity and specificity and still evolving knowledge about genetic aberra-
tions, family history is presently the only tool by which these syndromes can be recognized. Hence, a
detailed family history, including second and third degree relatives of both maternal as well as paternal
lineage could provide a strong basis for recognition of HOCS and evolving plans for surveillance, early
detection and management of siblings belonging to these high risk families.
The pedigree analysis in case of family 1 favours a diagnosis of breast ovarian cancer syndrome with a
predilection for early age at onset. Detailed pedigree analysis suggests that gene carrier probably is of
paternal lineage. The family had many members in the field of medicine and on counselling readily
understood the implications of this probable diagnosis for the rest of the family members. This has
helped in counselling this extended family residing in many different cities of Pakistan regarding future
surveillance. DNA analysis for BRCA-1 and other genes is in progress.
The analysis of family 2 was initially suggestive of site specific ovarian cancer of maternal lineage.
Later on, detailed paternal history revealed a clustering of breast as well as ovarian cancer cases in the
paternal lineage. This family is still under investigation as more information is gathered about the rest
of the family members again scattered in different towns and cities.
The proband in family 3 was diagnosed at quite a later stage of the disease. She would have had a
chance of early diagnosis if she was having regular surveillance. Her pedigree is suggestive of site
specific ovarian cancer syndrome. She herself motivated other members of the family including her
daughters to undergo regular check-up. Currently. all three families are participating in genetic linkage
analysis being performed on selected members.. It is hoped that these hereditary cancers can be
prevented from progressing to advanced stages by regular surveillance and hence by early diagnosis.
Lvnch et al6 suggested that screening should start by age 30 and should include pelvic examination,
ultrasonography, Ca-125 levels and color flow Doppler imaging of the ovarian vascular tree at 6
monthly intervals. We feel the screening strategies may require to be started earlier if any of the family
members develops cancer before the age of thirty as in family I. Women whd have completed their
families are candidate for prophylactic oophrectorny. This strategy has certainly been helpful.
However, subjects should be informed that there is
still a small risk of peritoneal carcinomatosis7. Woman at risk of breast cancer should undergo monthly
self-examinations, three monthly breast examination by a physician after the age of 18 ahd should have
yearly mammograms after the age of 30. In Lynch II cancer family syndrome in addition to above,
colonoscopy and endometrial biopsy is also recommended. In future, results of genetic linkage analysis
might help in identifying those at high risk so that targeted screening could be provided to them and the
rest of the family members can be reassured. However, further work is required before all genes
involved in hereditary transfer can be detected.
Obtaining a reliable family history is not an easy task because of the recall bias and inadequate
information about the earlier generations. The fact that morn information is available about the
maternal side as females are better informed about their families is also an important factor.
Furthermore, obtaining detailed family history is time consuming. Itis also important that historical
information obtained should be supplemented by review of medical records whenever possible.
In summary genetic counselling of such families in terms of identification, workup and follow-up is a
difficult but important task. Although members of such families are usually highly motivated but it
requires administrative setup and professional expertise to provide adequate service to every one
involved. The information regarding familial occurrence of cancer and its implications should be
disseminated in the lay press as well as the medical community. It is often difficult, if not impossible,
for one physician to follow extended families. Therefore, collaborative efforts at regional or national
level with the formation of familial cancers registries should be promoted to improve the follow-up of
these individuals.
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